Adaptive Biotechnologies (ADPT) Tops Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Adeptus Biotechnologies Corp. (ADPT) PT Raised to $11 at Morgan Stanley
August 6, 2025 7:56 AM EDTMorgan Stanley analyst Tejas Savant raised the price target on Adeptus Biotechnologies Corp. (NASDAQ: ADPT) to $11.00 (from $9.00) while maintaining a Equalweight rating.
The analyst comments "Another solid beat/raise as clonoSEQ volume/ASP momentum continues on payor traction, community/EMR uptake; MRD EBITDA... More
